4.4 Review

Sphingosine-1-Phosphate Signaling in Endothelial Disorders

期刊

CURRENT ATHEROSCLEROSIS REPORTS
卷 18, 期 6, 页码 -

出版社

CURRENT MEDICINE GROUP
DOI: 10.1007/s11883-016-0586-1

关键词

Atherosclerosis; Coronary artery disease; Microvascular dysfunction; Blood-brain barrier; Brain edema; Neurovascular injury; Hemorrhagic transformation; Malignant middle cerebral artery syndrome; Stroke reperfusion therapies; Vasogenic edema; Non-reflow phenomenon; Microcirculation; Immunosuppression; Translational research

资金

  1. NIH [HL094465]
  2. American Heart Association [12GRNT12050110]
  3. Department of Surgery
  4. Department of Emergency Medicine
  5. Beth Israel Deaconess Medical Center
  6. Department of Pathology and Laboratory Medicine, Weill Cornell Medical College

向作者/读者索取更多资源

Numerous preclinical studies indicate that sustained endothelial activation significantly contributes to tissue edema, perpetuates the inflammatory response, and exacerbates tissue injury ultimately resulting in organ failure. However, no specific therapies aimed at restoring endothelial function are available as yet. Sphingosine-1-phosphate (S1P) is emerging as a potent modulator of endothelial function and endothelial responses to injury. Recent studies indicate that S1PR are attractive targets to treat not only disorders of the arterial endothelium but also microvascular dysfunction caused by ischemic or inflammatory injury. In this article, we will review the current knowledge of the role of S1P and its receptors in endothelial function in health and disease, and we will discuss the therapeutic potential of targeting S1PR not only for disorders of the arterial endothelium but also the microvasculature. The therapeutic targeting of S1PR in the endothelium could help to bridge the gap between biomedical research in vascular biology and clinical practice.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据